Sweat gland cancer
diseaseOn this page
Also known as cancer of sweat glandmalignant neoplasm of sweat glandmalignant neoplasm of the sweat glandmalignant sweat gland neoplasmmalignant tumor of sweat glandmalignant tumor of the sweat glandmalignant tumour of sweat glandmalignant tumour of the sweat glandsweat gland neoplasms, malignant
Summary
Sweat gland cancer (MONDO:0002206) is a cancer and 1 clinical trial. Top therapeutic interventions include nivolumab and talimogene laherparepvec. A subtype of sweat gland neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | sweat gland cancer |
| Mondo ID | MONDO:0002206 |
| DOID | DOID:2095 |
| NCIT | C4810 |
| UMLS | C1321904 |
| MedGen | 231171 |
| Anatomy (UBERON) | UBERON:0001820 |
| Is cancer (heuristic) | yes |
Also known as: cancer of sweat gland · malignant neoplasm of sweat gland · malignant neoplasm of the sweat gland · malignant sweat gland neoplasm · malignant tumor of sweat gland · malignant tumor of the sweat gland · malignant tumour of sweat gland · malignant tumour of the sweat gland · sweat gland cancer · sweat gland neoplasms, malignant
Disease family
This is a subtype of sweat gland neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › skin neoplasm › epidermal appendage tumor › sweat gland neoplasm › sweat gland cancer
Related subtypes (5): eccrine sweat gland neoplasm, syringoma, apocrine sweat gland neoplasm, sweat gland adenoma, benign neoplasm of sweat gland
Subtypes (4): apocrine sweat gland cancer, malignant syringoma, eccrine sweat gland cancer, sweat gland carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02978625 | PHASE2 | ACTIVE_NOT_RECRUITING | Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NIVOLUMAB | 4 | 1 |
| TALIMOGENE LAHERPAREPVEC | 4 | 1 |
Related Atlas pages
- Drugs: Nivolumab, Talimogene Laherparepvec